Impact of adding bevacizumab to presurgery chemo for triple-negative breast cancer varies with subtype

Bookmark and Share
Published: 12 Dec 2014
Views: 2869
Dr William Sikov - Women and Infants Hospital, Providence, USA

In a press conference at SABCS 2014, Dr Sikov presents the results of his work on combination therapies based on cancer subtype.

Among women with triple-negative breast cancer, the benefit of adding bevacizumab to standard presurgery chemotherapy was greater for those whose cancers were classified as "basal-like" compared with those whose cancers were "nonbasal-like."

Read the news story or watch the interview for more. Also see comment from Prof Arteaga.